Timing and Delays in Breast Cancer Evaluation and Treatment
- 2 July 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 25 (10), 2829-2838
- https://doi.org/10.1245/s10434-018-6615-2
Abstract
Even small delays in the treatment of breast cancer are a frequently expressed concern of patients. Knowledge about this subject is important for clinicians to counsel patients appropriately and realistically, while also optimizing care. Although data and quality measures regarding time to chemotherapy and radiotherapy have been present for some time, data regarding surgical care are more recent and no standard exists. This review was written to discuss our current knowledge about the relationship of treatment times to outcomes.Keywords
This publication has 57 references indexed in Scilit:
- Delays in diagnosis and treatment of breast cancer: a multinational analysisEuropean Journal of Public Health, 2013
- Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysisBMC Cancer, 2013
- Timing of Radiotherapy and Outcome in Patients Receiving Adjuvant Endocrine TherapyInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Breast cancer tumor growth estimated through mammography screening dataBreast Cancer Research, 2008
- Radiotherapy waiting times for women with breast cancer: a population-based cohort studyBMC Cancer, 2007
- Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM)Breast Cancer Research and Treatment, 2006
- Hereditary breast cancer growth rates and its impact on screening policyEuropean Journal of Cancer, 2005
- The Sequencing of Chemotherapy and Radiation Therapy after Conservative Surgery for Early-Stage Breast CancerNew England Journal of Medicine, 1996
- Breast cancer during pregnancy: quantifying the risk of treatment delayObstetrics & Gynecology, 1996
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995